Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
PONTE VEDRA, Fla., July 17, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the next Emerging Growth Conference, a virtual forum for institutional and retail investment community engagement.
美國佛羅里達州龐特韋德拉，2024年7月17日 /美通社/ -- Cadrenal Therapeutics公司（納斯達克：CVDK）是一家生物製藥公司，正在開發Tecarfarin，這是一種新一代的維生素K拮抗劑（VKA）口服可逆抗凝劑（血液稀釋劑），旨在預防罕見心血管疾病患者因血栓引起的心臟病發作、中風和死亡。今天宣佈，公司將參加下一個Emerging Growth Conference，這是一個爲機構和零售投資社區提供虛擬交流的論壇。
Cadrenal's presentation will be on Thursday, July 18, 2024, at 4:15 pm ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed here.
Cadrenal的演講將於2024年7月18日星期四下午4:15（ET）舉行。演示文稿的網絡廣播鏈接可以在公司網站的投資者關係頁面上找到或在此處訪問。
If interested investors are not able to join the live event, an archived webcast will be available on and the Emerging Growth YouTube Channel, .
如果有興趣的投資者無法參加現場活動，可以通過 Emerging Growth 的YouTube頻道鏈接觀看活動的存檔網絡廣播。
Management will also host one-on-one investor meetings after the Conference. To request a virtual one-on-one meeting with the Company's management team, please contact your Emerging Growth Conference representative or email the Company's investor relations team at [email protected].
在會議後，管理團隊還將舉行一對一的投資者會議。如果您想要請求與公司管理團隊的虛擬一對一會議，請聯繫您的Emerging Growth Conference代表或發送電子郵件至公司投資者關係團隊[email protected]。
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions who require lifelong anticoagulation. Tecarfarin has orphan drug designation from the FDA for the prevention of thrombosis and thromboembolism (blood clots) in patients with an implanted mechanical circulatory support device, which includes the left ventricular assist device (LVAD). Tecarfarin also has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically designed to use a different metabolism pathway than the oldest and most commonly prescribed VKA warfarin. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: .
關於Cadrenal Therapeutics，Inc.
Cadrenal Therapeutics正在開發Tecarfarin以滿足抗凝治療的未滿足需求。 Tecarfarin是一種新一代的維生素K拮抗劑(VKA)口服和可逆性抗凝劑(減薄機)，旨在預防罕見心血管疾病患者的心臟病發作、中風和死亡因血栓而引起的情況，在需要終身抗凝治療的情況下。Tecarfarin已獲得FDA的孤兒藥標誌，用於預防植入機械循環支持裝置的患者的血栓和血栓栓塞(血栓) ，包括左室輔助裝置(LVAD)。Tecarfarin還獲得了FDA的孤兒藥和快速通道標誌，用於預防終末期腎病(ESKD)和心房顫動(AFib)患者的心源性全身性血栓栓塞。Tecarfarin採用與最古老和最常規處方的VKA華法林不同的代謝途徑進行設計。 Tecarfarin已經進行了11項人體臨床試驗，涉及1000多名個體。在一期、二期和二期/三期臨床試驗中，Tecarfarin在健康成年受試者和慢性腎臟病患者中通常耐受良好。欲了解更多信息，請訪問： .
For more information, please contact:
更多信息，請聯繫：
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
[email protected]
Cadrenal Therapeutics:
CFO馬修·索特（Matthew Szot）
858-337-0766
[email protected]
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
[email protected]
投資者：
Lytham Partners, LLC
Robert Blum，管理合夥人
602-889-9700
[email protected]
SOURCE Cadrenal Therapeutics, Inc.
來源：Cadrenal Therapeutics，Inc。
譯文內容由第三人軟體翻譯。